Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (12295)	11/21/1999 11:38:00 PM
From: Bluegreen	Read Replies (2) \| Respond to of 17367

I would suggest one might contact someone at Xoma that can clear up EXACT and COMPLETE parameters of Hemo Trauma trial before speculating.

To: Robert K. who wrote (12295)	11/22/1999 3:45:00 PM
From: franksja	Respond to of 17367

"..patients who receive two or more units of blood as a result of blunt or penetrating trauma. " There must be more to the criteria than that. It seems to me that the two or more pints would have to be after the blood loss as a result of trauma(a deficit in the total supply). In other words, the patient loses the blood, causing the system to redirect the blood to the vital organs (away from the guts). This loss of circulation in the intestional track by loss of blood pressure allows the bacteria to cross from the gut to the blood stream, causing infection in the blood. In the case of surgery, where the blood is being replaced as the loss occurs, this situation would not exist and there would be no cross flow of bacteria. I may be all wet with this speculation, but that was the way I had figured it out. In other words, the trial would be in those cases where the severe blood loss had occurred before any transfusion had occurred. If I am correct, the mere receipt of two or more pints is an inadequate test for Neuprex.